Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-Cell Therapy

NCT04409314 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04409314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04409314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-Cell Therapy
Lead sponsor
University of California, San Francisco
Phase
Observational
Overall status
Completed
Start date
April 16, 2020
Completion date
August 9, 2023
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent aggressive non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, recurrent high grade b-cell lymphoma, recurrent malignant neoplasm, recurrent plasma cell myeloma, recurrent primary mediastinal (thymic) large b-cell cell lymphoma, refractory aggressive non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory high grade b-cell lymphoma, refractory malignant neoplasm, refractory plasma cell myeloma, refractory primary mediastinal (thymic) large b-cell cell lymphoma